Loading clinical trials...

Back to clinical trial search

AVAILABLENCT04745637

Managed Access Programs for INC424, Ruxolitinib

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

Lead sponsor: Novartis Pharmaceuticals•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs

CONTACT

1-88-669-6682 novartis.email@novartis.com

Novartis Pharmaceuticals

CONTACT

+41613241111

Related studies

RECRUITINGPhase 3

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), and more

Not Yet RecruitingPhase 1

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

NCT07340138 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), and more

COMPLETEDPhase 1/2

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

NCT03136185 · Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 18, 2025Terms

Trial snapshot

StatusAVAILABLE

Phase—

Enrollment—

Start date—

Last updatedNov 18, 2025

Condition

Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Thrombocythemia Myelofibrosis (PET-MF)Severe/Very Severe COVID-19 Illness Polycythemia Vera (PV)

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 18, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions